Effect of Nutrition Risk Screening 2002-guided enteral nutrition on nutritional status in gastrointestinal tumor patients

2002年营养风险筛查指导下的肠内营养对胃肠道肿瘤患者营养状况的影响

阅读:1

Abstract

BACKGROUND: Malnutrition exacerbates the deterioration in patients with advanced gastrointestinal tumors. AIM: To analyze the effect of enteral nutritional support based on Nutrition Risk Screening 2002 (NRS2002) risk assessment on nutritional function in patients with gastrointestinal tumors. METHODS: One hundred twelve patients from April 2022 to April 2024 were included for observation and were divided into a control group and an observation group by random number method, 56 each. Both groups received treatment for four consecutive weeks. The control group received routine enteral nutrition support, while the observation group received enteral nutrition support based on the NRS2002 risk assessment. Nutritional function, intestinal mucosal barrier function, quality of life, and complication rate were compared between the two groups. Statistical analysis was completed using SPSS26.0 and Excel. RESULTS: After nutritional intervention, transferrin, albumin, hemoglobin, and diamine oxidase levels in the observation group were higher than those in the control group, while C-reactive protein, tumor necrosis factor α, and quality of life scores were lower, with significant differences (P < 0.05). There was no significant difference in complications between groups (P > 0.05), but the complication rate was lower in the observation group. CONCLUSION: Enteral nutritional support based on NRS2002 risk assessment for patients with gastrointestinal tumors positively impacts nutritional status and promotes intestinal mucosal barrier function recovery. Patients' quality of life improved, and the incidence of adverse reactions decreased, indicating clinical promotion and application value.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。